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Background: Parkinson’s disease (PD) is a chronic neurodegenerative disorder with limited knowledge about the
normal function and effects of non-pharmacological therapies on the hypothalamic-pituitary-adrenal (HPA) axis. The
aim of the study was to analyse the basal diurnal and total secretion of salivary cortisol in short- and long-term
aspects of tactile massage (TM).
Methods: Design: Prospective, Controlled and Randomised Multicentre Trial.
Setting and interventions: Forty-five women and men, aged 50–79 years, were recruited. Twenty-nine of them were
blindly randomised to tactile massage (TM) and 16 of them to the control group, rest to music (RTM). Ten
interventions were given during 8 weeks followed by a 26 weeks of follow up. Salivary cortisol was collected at 8
am, 1 pm, 8 pm, and 8 am the next day, on five occasions. With the first and eighth interventions, it was collected
immediately before and after intervention.
Main outcome measures: The primary aim was to assess and compare cortisol concentrations before and
immediately after intervention and also during the follow-up period. The secondary aim was to assess the impact
of age, gender, body mass index (BMI), duration and severity of PD, effects of interventional time-point of the day,
and levodopa doses on cortisol concentration.
Results: The median cortisol concentrations for all participants were 16.0, 5.8, 2.8, and 14.0 nmol/L at baseline, later
reproduced four times without significant differences. Cortisol concentrations decreased significantly after TM
intervention but no change in diurnal salivary cortisol pattern was found. The findings of reduced salivary cortisol
concentrations immediately after the interventions are in agreement with previous studies. However, there was no
significant difference between the TM and control groups. There were no significant correlations between cortisol
concentrations and age, gender, BMI, time-point for intervention, time interval between anti-parkinson pharmacy
intake and sampling, levodopa doses, duration, or severity of PD.
Conclusions: Diurnal salivary cortisol rhythm was normal. Salivary cortisol concentrations were significantly reduced
after the TM intervention and after RTM, but there were no significant differences between the groups and no
sustained long-term effect. No associations were seen between salivary cortisol concentration and clinical and/or
pharmacological characteristics.
Trial registration: ClinicalTrial.gov, NCT01734876 and FoU Sweden 108881.
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Why study the hypothalamic-pituitary-adrenal (HPA) axis
in PD?
Parkinson’s disease (PD) is a chronic progressive neurode-
generative disorder accompanied by autonomic dysfunc-
tion and alterations in different regulatory mechanisms [1].
Typically, signs of PD are hypokinesia, rigidity, and tremor.
Non-motor symptoms (NMS) such as mood changes, pain,
and autonomic dysfunctions are frequent [2-4]. Many PD
patients suffer from sleep disorders, apathy, tiredness, an-
orexia, and instability (hypotension). These symptoms can
mimic reduced adrenal cortisol activity.
Health-related quality of life (HRQoL) is poor in people
with PD compared with other disabled populations [5]. As
the disease progresses, motor and non-motor complica-
tions become more severe, making patients’ adherence
to medication even more important. A complicated dos-
ing or titration schedule is a part of daily life in PD [6].
In addition to pharmacological treatment, there are
non-pharmacological approaches aimed at alleviating
the symptoms of PD. Complementary and alternative
methods (CAM) are commonly used in PD patients [7].
Acute and chronic stress seem to raise the function of
the hypothalamic-pituitary axis in terms of elevated
concentrations of cortisol [8-10]. Several studies have
shown salivary cortisol concentration to be an excellent
mirror of hypothalamic-pituitary axis function [11],
with fast reactions to changes in the surroundings [12].
We hypothesised that this would be a natural biomarker
for stress in our study. In a previous study by our group,
we found that median morning salivary cortisol concen-
trations and total cortisol secretion during the day were
higher in PD than in an age- and sex-matched healthy
reference group [8]. In a previous study by Hartmann
[13], total serum cortisol was analysed every 15 min for
24 h. They found a higher diurnal cortisol secretion in
PD compared with a healthy reference group. This study
was very intensive, took place in a hospital situation,
and did not analyse free biologically active cortisol.
Could these results be a consequence of stress in the
sampling situation?
Later studies have shown that free biologically active
cortisol increases much more than total cortisol in situa-
tions of stress, intensive care, and so on [12]. Literature
findings in 2003, when this study began, were sparse.
There was no other similar study that had analysed diur-
nal cortisol secretion in PD during and after interven-
tions and during a long follow-up period.
To confirm or reject the previous findings, we per-
formed this study in a group of healthy patients with
well-defined PD for a duration of more than 2 years.
Their only medications were for PD and for chronic
pain, and the disease was not so severe that they needed
subthalamic deep brain stimulation, continuous releaseof levodopa in their duodenal bulb (Duo-Dopa), or apo-
morphine injections.
What is the primary causal factor in HPA axis
dysregulation: consequences of ageing, stress, or PD
itself?
In a previous study, we compared the HPA axis function in
PD patients with and without chronic pain [8]. Chronic
pain was defined as significant PD-related pain more than
three times/week during at least 3 months before inclusion.
We compared salivary cortisol of PD patients with an age-
and sex-matched healthy reference group. These analyses
were performed identically and in the same laboratory. We
found higher morning cortisol in both PD groups com-
pared with the reference group. There was no significant
difference between PD with and without chronic pain [8].
In a 76-year-old female, the diurnal cortisol curve was very
prominent, with very high morning cortisol concentrations,
in agreement with a well-functioning circadian rhythm.
In summary, the HPA axis seems to be up-gradated in
PD patients without other disorders (somatic, psychi-
atric). The chronic pain (=stress) resulted in no differ-
ence. We found no correlation between salivary cortisol
concentration (HPA axis function) and age, sex, BMI,
adjusted daily dose of levodopa, or time interval be-
tween medication ingestion within 1 h either side of sal-
ivary sampling [8]. Therefore, PD itself seems to result
in HPA axis dysregulation.
Massage therapy
The Greek physician Hippocrates (460–377 B.C.) advo-
cated rubbing as a treatment for stiffness and massage
was the primary form of care for stiffness until the
pharmaceutical revolution of the 1940s. Massage therapy
has received empirical support for facilitating growth,
reducing pain, increasing alertness, diminishing depres-
sion, and enhancing immune function [14].
In agreement with these historical experiences, mas-
sage therapists in our region have also experienced ex-
cellent effects on relaxation, reduced pain, increased
motor function, and improved sleep in PD patients.
Stress tolerance is low in this type of patient; HRQoL is
known to be worse than in age- and sex-matched
healthy persons as well as in patients with other chronic
disorders such as stroke [15,16]. In an attempt to study
the effects of this non-pharmacological approach on
HPA axis function and some of the associated NMS
such as pain and sleep disturbances, the Parkitouch
study was initiated with the intention to report the ef-
fects of TM on salivary cortisol concentrations.
Main outcome measures
The primary aim was to assess and compare cortisol
concentrations before, during, and immediately after
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follow-up period. The secondary aim was to assess the
impact of age, gender, body mass index (BMI), duration
and severity of PD, effects of interventional time-point of
the day, and levodopa doses on cortisol concentration.
Methods
Subjects
Patients with stable and well-defined PD for more than
2 years who fulfilled the established clinical criteria for
diagnosis and with chronic pain were recruited from the
outpatient departments of three medium-sized city hospi-
tals in southern Sweden. Chronic pain was defined as the
occurrence of PD-related pain for 3 days or more per week
during at least 3 months prior to inclusion. Exclusion cri-
teria were severe fluctuations in PD, concurrent existence
of epilepsy, active malignancy, polyneuropathy, or other
serious disease of somatic or psychiatric origin that could
interfere with the study. Patients with severe abnormalities
of blood parameters, electrolytes, liver or renal parameters
such as bilirubin >20 mmol/L, creatinine >130 mmol/L,
sedimentation rate >30 mm, or p/glucose > 6.7 mmol/L
(fasting) were also excluded. Participation in other studies
was not allowed.
Pharmacological treatment
The patients had medication only for PD, and for
chronic pain, mainly non-steroidal anti-inflammatory
drugs (NSAID). We adjusted for the total levodopa
equivalent dose for their dopamine agonists.
Unified Parkinson Disease Related Scale (UPDRS)
UPDRS questionnaires I–IV were used to classify the
participants into different groups in relation to cognition,
mood, performance, motor function, activities of daily liv-
ing, and adverse reactions to their medication [17].
Procedures
To optimise our study design, salivary cortisol was sam-
pled in the patients’ homes to minimise stress. This was
done at exact time points according to detailed written
instructions for sampling and storage of the samples in
their refrigerator before sending the collected samples to
the laboratory. All samples, five diurnal curves and six
samples from two interventions (n = 26) from each per-
son, were analysed at the same time point to minimise
the intra- and inter-assay coefficients of variance (CV).
Study design, recruitment, and randomisation
Participants were recruited from September 2004 to
January 2009. The study was controlled and prospective,
and the participants were randomised by computer to ei-
ther tactile massage (TM) or the control group (RTM)
by a lottery procedure. We had no adjustment with ablock strategy in the randomisation procedure. All patients
gave their written informed consent. An independent
member of the Parkitouch Study Group was responsible
for enrolment of all participants by communicating the
blinded, computerised randomisation course. She informed
the nurse by a telephone call. She took a prenumbered
envelope from a box, opened the closed envelope, and in-
formed about what type of individual intervention the par-
ticipant should be given. Thereafter, she put the envelope
back in the box.
For details about enrolment, intervention allocation,
follow-up, and analysis see the CONSORT 2010 flow
diagram (Figure 1) [18].
Patients visited the outpatient clinic of the respective
hospitals during the 34-week study period (Figure 2).
Two interventions per week were performed during the
first 3 weeks and thereafter, one intervention was per-
formed per week. The 10th intervention was performed
8 weeks after randomisation, followed by a 26-week
follow-up.
Study intervention
All sessions were predetermined to be performed during
the period between 9 am and 12 am. During TM, a
specific oil was used, Fibro oil from Crearome AB,
Gamleby, Sweden, mixed with Virgin oil comprising
one-third of the total volume. TM was performed fol-
lowing detailed instructions, written in 2003 by licensed
massage therapists and co-authors Laila Robertsson and
Birgitta Larsson (see Additional file 1). They certified the
competence of the participating local massage therapists.
All individual TM interventions were given by the same
therapist.
Patients randomised to RTM had the same external
conditions. RTM was given in the same location as TM,
with the same duration, and the other circumstances
were identical to TM excluding the specific massage.
The music was identical in both groups: Music for well-
being II – Letting go of stress (LC6607 Fönix Musik,
Sweden). The participants could regulate the sound level
to a comfortable level.
Collection of salivary cortisol samples
All time points for sampling were registered exactly in a
protocol. For both groups, collection of salivary samples
was done using a well-described technique [19]. In
short, a cotton-based neutral swab was used; teeth
should not be brushed and no food should be eaten
within 30 min before sampling. Thereafter, a neutral
swab was chewed for 2 min and later, the swab was
placed in a plastic double lumen tube. Then, the tube
was placed in a refrigerator at home until it was sent for
further analysis within 3 days. In the lab, it was centri-
fuged at 3,000 rpm for 10 min at room temperature,
Follow - Up
Analysed (n=29)
Excluded from analysis  (n=0)
Analysis
Analysed (n=15)
Excluded from analysis (n=0)
Lost to follow-up (n=0)
Discontinued intervention (n=0)
Lost to follow-up (n=0)
Discontinued intervention (n=0)
Enrollment
Allocated to Tactile massage (n=29) 
Received allocated intervention (n=29)
Allocation
Allocated to Rest to music (n=16)  
Received allocatedintervention (n=15) 
Did not receive allocated intervention 
(n=1) (illness of relative)
Randomised (n=45)
Excluded (n=15)
Not meeting inclusion criteria (n=15)
Declined to participate (n=0)
Other reasons (n=0)
Assessed for eligibility (n=60)
Figure 1 The CONSORT 2010 flow diagram.
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samples were analysed at the same time. The time-
points for sampling were 8 am, 1 pm, 8 pm, and 8 am
the next day and before, immediately after, and 30 min
after intervention was finished. A commercial RIA-based
technique for measurement of salivary cortisol was used
(Spectria Cortisol I125 TM, Landskrona, Sweden).
Measures
The total secretions of cortisol during the day, from
8 am–8 pm, and during the night, from 8 pm–8 am,
were calculated using the formula for area under curve
(AUC) from the zero level (AUC0 = AUCG), according
to investigations of Preussner [20] and Fekedulegn [21].
All analyses of saliva from the same individual (n = 26)
were performed simultaneously. Salivary cortisol during
the day was measured at baseline, at 3, 8, 21, and 34 weeks
after randomisation. In addition, the immediate effects
(just before, immediately after, and 30 min after the inter-
vention was finished) were measured at the first and the
eighth interventions.
Statistical analysis
STATISTICA version 8.0 and 10.0 (STATsoft Inc. Tulsa,
OK, USA) and SPSS version 18.0 (SPSS Inc, Chicago, IL,USA) were used for the statistical evaluations. Non-
parametric tests were used to adjust for the skewness in
the subjects. Mann–Whitney U test and Kruskal-Wallis
one-way analysis of variance (ANOVA) were used to
compare the two groups. Friedman’s ANOVA was used
to compare the diurnal cortisol rhythm and total cortisol
secretion during the five study time-points. Wilcoxon’s
matched-pairs signed-rank test was used to analyse indi-
vidual diurnal rhythms and Spearman rank order correl-
ation test was used to analyse the association between
cortisol and clinical characteristics. All tests were two-
sided and statistical significance was assumed at p < 0.05.
Power: In order to have a 20% difference in cortisol
concentration (AUC) between groups, a total of 40 pa-
tients were needed to have 90% power with a signifi-
cance level of 0.05.
Ethics
The study was approved by the Ethics Committees at
the University of Gothenburg (Ö 76203) and the Univer-
sity of Linkoping (D 03–673), Sweden.
Results
Our study included 45 participants randomised to TM
(n = 29) or RTM (n = 16). One participant in the RTM
Time axis
Week (-1)       21
Type Screening           Intervention Follow up
1              TM / RTM 10                                               
Evaluations           A
Footnote
A Week  -1, 3, 7, 21, 34 = Salivary cortisol A1, VAS max-scale3,UPDRS I-IV4(at screening,week 7, 11
and 21) , Drug list 5
B week 0, 5 = Salivary cortisol B2, VAS max-scale3, Drug list5
C week 10, 14 = VAS max-scale3, Drug list5
Explanations:
1 = Salivary cortisol A: Salivary cortisol measured at 8am, 1pm, 8pm and 8am next day. 
2 = Salivary cortisol B:Salivary cortisol measured immediately before, immediately after and
30 minutes after intervention, respectively.
3 = Visual Analogue Scale, maximal pain for five consecutive days before intervention.
4 = Unified Parkinson Disease Rating Scale part I-IV.
5 = Drug list: Evaluation of the patient´s actual pharmacotherapy.
0
AB A A ACCB
3 7 11 14 34
Figure 2 Time axis, interventions for Tactile massage and Rest to music groups.
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because of disease in the family. There were no import-
ant harms or unintended effects that resulted in the dis-
continuation of intervention. Clinical and demographic
characteristics at baseline were similar between groups
(Table 1).
Follow-up rates were 100% and 93%, respectively. The
natural diurnal negative slope of cortisol concentrations
between 8 am and 1 pm was estimated to 2.0 nmol/h.
Comparisons between TM and RTM groups at the time-
points for awakening, sampling, interventions, and corti-
sol concentrations, delta cortisol, percentage changes of
cortisol concentration, and total cortisol secretion dur-
ing and within 30 min after intervention (AUC) are
shown in Table 2.Table 1 Clinical and demographic characteristics of the two P
Group Sex Age1 Weight2
“Tactile massage” Male (n = 10) 50-78 86.5 (68.1/10
Female (n = 19) 60-79 64.7 (54.8/95
“Rest to music” Male (n = 6) 50-74 88.6 (62.0/10
Female (n = 9) 50-74 70.8 (44.5/92
Values are given as range1 and medians/10th and 90th percentiles2. Hoehn and Yah
There were no statistical differences between the groups or gender. (Statistical metPharmacological treatment
No significant differences between the two groups were
seen even when we integrated other forms of anti-PD
drugs and recalculated the total dopaminergic load using
formulas from the literature [22]. Forty-two of 44 patients
were treated with levodopa with a median total dose of
625 mg/day after recalculation. The pharmacological
treatment was essentially unchanged and only single extra
doses of anti-PD treatment were taken during the study.
Massage
The TM was performed for each individual patient by
the same therapist for a mean duration of 52 minutes
per session (range 40–79 minutes), with a total of 10
massages during a period of 8 weeks. At the first andD populations at baseline
BMI2 H&Y 2,3 UPDRS (I-IV) 2,4
3.4) 26.6 (24.1/37.4) 1.5 (1.0/2.5) 31.5 (24.1/46.4)
.0) 25.0 (20.2/35.9) 2.5 (1.5/3.1) 39.0 (27.5/61.2)
2.0) 27.0 (23.6/31.5) 3.0 (1.5/3.0) 42.5 (32.0/57.0)
.4) 24.2 (17.8/31.2) 2.0 (1.0/4.0) 39.0 (21.0/78.0)
r3, Unified Parkinson’s Disease Rating Scale4.
hod: Mann–Whitney U-test).
Table 2 Baseline variables and cortisol concentrations at first and eighth intervention split by arms
RTM (n = 14) TM (n = 28)
Age (year) 62.5 (54–73) 66.0 (61–73)
Gender (m/f) 6/8 10/18
Time of wakening
First/eighth intervention 04.30-07.30 02.00-07.30
04.30-08.00 04.00-08.00
Time of sampling
First/eighth intervention 07.20-15.35 08.00-15.49
08.00-15.12 07.51-15.15
Time interval after wakening (min) 90-585 110-543
55-578 40§-555
Cortisol (nmol/L) (median/10/90%)
Before first/eighth intervention 7.0 (4.5/23.9) 9.2 (4.1/17.0)
7.2 (4.1/23.9) 7.5 (4.5/13.8)
After 0′ 6.3 (2.6/18.7) 6.8 (2.5/15.4)
6.6 (2.5/11.0) 5.7 (3.5/9.8)
After 30′ 6.6 (2.4/8.3) 5.6 (2.6/13.2)
4.8 (2.5/21.1) 4.6 (2.6/9.2)
Delta Cortisol (nmol/L)
Before - after 0′
First/eighth intervention 1.8 (−3.0/+5.5) 1.9 (−2.0/+6.2)
2.6 (−2.5/+17.1) 1.7 (−2.0/+5.4)
Before- after 30′
First/eighth intervention 2.4 (−0.3/+17.1) 3.4 (−2.2/+6.5)
3.6 (−0.1/+13.2) 3.1 (−2.8/+7.5)
Percentage difference in Cortisol
Before - after 0′
First/eighth intervention 26.8 (−41.0/+42.4) 27.7 (−2.2/+55.4)
38.8 (−38.5/+58.8) 26.1 (−30.9/+53.8)
Before- after 30′
First/eighth intervention 45.8 (−4.5/+71.5) 33.3 (−12.9/+60.7)
11.3 (−45.5/+29.2) 11.6 (−28.0/+43.7)
Cortisol AUCG
Before - after 0′
First/eighth intervention 350 (143/1271) 456 (189/954)
338 (173/1030) 352 (221/656)
Before- after 30′
First/eighth intervention 582 (255/1939) 662 (267/1366)
562 (262/1614) 491 (303/854)
Footnote: TM = Tactile massage, RTM = Rest to music. AUCG = area under curve from ground level.
Statistical methods used; Mann–Whitney-U, Chi-2-test, Median test and Kruskal-Wallis test. There were no statistical differences between groups. Eight time inter-
vals < 60 min. at 8th intervention and once at first intervention. §This patient had concentrations, 7.7, 9.7, and 10.2 nmol/L, excluding a cortisol arousal
reaction (CAR).
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293) and 109 (10–272) minutes, respectively, after intake
of the morning PD medication.All interventions were performed before 12 am, ex-
cept in the case of three participants, from each type of
intervention at first and eighth sessions. There was no
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tween early and late interventions.
Salivary cortisol
Basal and short- and long-term effects of intervention on
cortisol concentrations are shown in Figure 3 and Tables 2
and 3. At baseline, there was no significant difference
between the groups. Salivary cortisol concentrations at
baseline before the first intervention and at week 3, after
the sixth intervention, were not significantly different be-
tween groups, as shown in Table 3. A comparison of the
two groups regarding the total diurnal secretion of cortisol




In Tables 4 and 5, differences in total cortisol secretion,
at screening (AUC-screening) and during the separate
interventions (AUC-intervention) are shown.
After the first intervention, there was a significant de-
crease in salivary cortisol concentration in the TM group
but not in total secretion (AUC) immediately after the
intervention. In contrast, 30 min after the intervention,
salivary cortisol concentrations were significantly decreased
in both TM and RTM but the total cortisol secretion
(AUC) was not changed in any group (Figure 3 and
Tables 4 and 5).
After the eighth intervention, salivary cortisol concentra-
tions were significantly decreased immediately and 30 min
after intervention in both groups (Figure 3). Total salivary




















Before 0min 30min Before 0min 30m
First Eighth
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Figure 3 Short term effects of Tactile massage and Rest to music onimmediately after the intervention in both groups but
remained decreased only in the TM group (Tables 4
and 5).
Tables 4 + Table 5* Area under the Curve (AUC) for
short-term effects, before to 0 minutes after intervention
(4) and Area under the Curve (AUC) for short-term ef-
fects, before to 30 minutes after intervention (5).
We found no differences between groups in delta cor-
tisol values and percentage changes after TM and RTM,
as shown in Table 2. The immediate effects of interven-
tion were not correlated to interventional time-point of
the day (morning/afternoon), age, gender, BMI, or the
duration of disease.Long-term effects
The diurnal cortisol concentrations are shown in Table 3.
We compared the diurnal cortisol curve at baseline and
during the study period (weeks 3, 8, 21, and 34). We
found no change in diurnal rhythm or absolute cortisol
concentrations during 26 weeks of follow-up. At baseline
and after 3 weeks of the intervention period, the total
cortisol secretion was higher during the night (8 pm–
8 am) than day (8 am–8 pm) in both the TM group and
the control group. Total cortisol secretion during the
day was not significantly different between the TM and
RTM groups.Associations between salivary cortisol, clinical
characteristics, and intervention
No associations were found between salivary cortisol









Table 3 Diurnal salivary cortisol concentration during intervention and follow up period
WEEK Tactile massage Rest to music p-values1
8 am 1 pm 8 pm 8 am 8 am 1 pm 8 pm 8 am
0 14.3(5.8-28.9) 4.9(2.4-23.3) 2.8(1.6-7.1) 14.0(6.9-35.0) 18.5(3.9-28.5) 6.2(3.7-10.0) 2.8(1.1-8.5) 17.0(7.6-28.6) ns
3 13.4(6.2-26.7) 6.3(3.1-10.1) 2.6(1.2-6.1) 14.1(6.7-29.5) 15.9(8.8-18.8) 3.9(3.0-10.5) 1.9(1.4-7.8) 12.4(8.1-34.0) ns
8 12.1(6.6-37.3) 4.9(2.9-14.3) 2.5(1.5-4.8) 14.0(7.6-34.9) 11.6(6.9-28.0) 5.1(2.7-10.3) 2.6(1.1-7.6) 12.6(5.6-28.2) ns
21 12.2(5.6-25.4) 6.2(3.5-18.4) 3.1(1.2-7.9) 13.2(6.5-26.9) 12.5(6.4-19.5) 6.0(3.5-8.0) 2.6(1.4-9.8) 14.3(6.2-42.0) ns
34 13.2(6.3-35.9) 7.3(3.5-16.8) 2.6(1.4-11.3) 15.1(5.7-32.0) 14.5(6.4-30.0) 6.4(3.2-11.0) 3.5(1.3-9.4) 13.4(7.0-40.9) ns
p-values2 ns ns ns ns ns ns ns ns
Results are given as median and 10th- 90th percentiles. The statistical methods used were Kruskal-Wallis1 comparing the two groups and Friedman’s ANOVA2 com-
paring the longitudinal process. ns = non-significant difference.
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or time-point or dose of levodopa intake.Discussion
In this study, we found an immediate effect (short-term
effect) of TM on the hypothalamic-pituitary axis, with a
significant decrease in cortisol concentration at both first
and eighth time-points after TM. However, there were
no significant differences between the TM and RTM
groups at these time-points in the decrease in cortisol
concentration. Nor were differences seen in cortisol con-
centrations between the groups due to the interventional
time-point of the day. The delta cortisol and absolute
values for salivary cortisol concentrations were similar in
the two groups. The percentage decrease after interven-
tion was more than 20% in both groups, which is in
agreement with the results of another study in cancer
patients receiving massage therapy [23]. To our surprise,
we found no significant correlations between cortisol con-
centration and age, gender, weight, BMI, or disease dur-
ation. Our results further suggest that the diurnal pattern
of cortisol secretion, i.e., the sensitivity of hypothalamic-
pituitary axis function, was normal at baseline, before the
intervention, and was unchanged during the interventions
and up to 26 weeks after the last treatment session.Table 4 Area under the Curve (AUC) for short-term
effects, before to 0 minutes after intervention
Group AUC screening1 AUC
intervention2
p-value3
First intervention RTM 553 (175-1118) 350 (143-1271) 0.249
TM 571 (219-1226) 456 (189-954) 0.153
Eighth intervention RTM 563 (188-1117) 338 (173-1030) 0.035*
TM 525 (242-1215) 352 (221-656) 0.003*
1 AUC estimated according to individual intervention time for start and
duration in minutes based on linear equation for daily AUC at screening.
Median (10th and 90th perc).
2 AUC according to intervention duration and salivary concentration at start, 0
min after and 30 min after. Median (10th and 90th perc).
3 AUC intervention compared to AUC screening, Wilcoxon’s test for
paired data.
*Statistically significant difference.Comparison of previous studies in this field
A recently published finding of the Parkitouch study was
significantly increased morning salivary cortisol concen-
tration compared with an age- and sex-matched healthy
group [8]. In 2002, Hernandez-Reif et al [24] performed
a pilot study on massage in PD patients, and to our
knowledge, this is the first study of the effects of mas-
sage on HPA axis function in PD. They found no differ-
ences in urine cortisol secretion after the first and last
interventions. However, in 2005 Field et al [25] showed
changes in cortisol concentrations in saliva after massage
therapy. This finding is in agreement with our results. A
review article of massage therapy combined with analysis
of cortisol in urine, saliva, or plasma in healthy and sick
adults by Moraska et al [26] summarises the studies up
to 2008. In eight studies, salivary cortisol was analysed
at the first and/or sixth to 10th interventions. In 89% of
studies, salivary cortisol concentration decreased after
the first intervention. In four out of eight studies, saliv-
ary cortisol also decreased after the last treatment. This
is in agreement with our results. Only one study has
shown a significant decrease in urine cortisol after mul-
tiple treatments. No study has analysed diurnal or mul-
tiple salivary cortisol samples during intervention. During
the passive non-interventional follow-up period, there was
no previously published study that had analysed diurnal
cortisol rhythm and/or multiple salivary cortisol samples.NMS
We did not include a self-reported mood questionnaire.
Nor did we use a specific, sensitive questionnaire for de-
pression and anxiety. However, our nurses and massage
therapists met each person 10–16 times at these inter-
ventions. No one seemed to be depressed or very anx-
ious, and no one reported signs of depression in the
UPDRS I questionnaire. Instead, we used specific question-
naires, Parkinson’s Disease Sleeping Scale (PDSS) and Short
Form (36) Health Survey (SF36) Swedish version 1.0, to
compare sleep pattern and HRQoL. We found disturbed
sleep and a low HRQoL, even lower than in patients who
Table 5 Area under the Curve (AUC) for short-term
effects, before to 30 minutes after Intervention
Group AUC screening1 AUC
intervention2
p-value3
First intervention RTM 875 (292-1641) 582 (255-1939) 0.158
TM 918 (337-1752) 662 (267-1366) 0.076
Eighth intervention RTM 870 (315-1686) 562 (262-1614) 0.087
TM 883 (373-1783) 491 (303-854) 0.004*
1 AUC estimated according to individual intervention time for start and
duration in minutes based on linear equation for daily AUC at screening.
Median (10th and 90th perc).
2 AUC according to intervention duration and salivary concentration at start, 0
min after and 30 min after. Median (10th and 90th perc).
3 AUC intervention compared to AUC screening, Wilcoxon’s test for
paired data.
*Statistically significant difference.
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have recently been published [27].
Interacting factors
Personal care and kind treatment are naturally of great
value in all patient care. The placebo effect is also of es-
sential importance, as described by Wormnes et al [28].
The TM method also included listening to tranquil and
peaceful music. The volume was adjusted by the individ-
ual participant to a comfortable level to avoid stress and
discomfort. In the pleasantly warm room, some smells of
plants (aroma) were present but it was not a specific
aromatherapy. To minimise and eliminate confounders
because of these conditions, treatment of the control
group (RTM) was identical in detail to that of the TM
group, except for the specific moderate TM of the skin.
The intention was to study the unique effect of this spe-
cific TM method and reduce the number of independent
variables; therefore, we performed the study with two
‘active’ groups where only the presence of TM differed.
Limitation of this study
Relatively few patients were included. The oldest PD pa-
tients were excluded due to difficulties in carrying out
the extensive programme, and the risk of falling or bal-
ance problems in conjunction with the interventions on
the massage table. However, compared with previous
studies combining massage therapy and analysis of corti-
sol, our study is the second largest of nine controlled
studies [26]. The distribution of participants between
TM and RTM was somewhat distorted, 2:1, which was
not our strategy at the start. However, as randomisation
was performed with a computerised lottery technique
and blinded, we had no influence on the distribution of
patients to the groups. As the RTM group was quite
small, it was possible that the spread of results within
this group hid significant differences between TM and
RTM (type II error). Therefore, a hypothetic comparison
between the TM and RTM groups with a similar numberof participants in each group (n = 28) was performed,
using identical cortisol results as for the first 14 RTM
participants. This theoretical model resulted in a signifi-
cant difference between some factors representing pain
and sleep, but not in the cortisol concentrations after in-
terventions with the TM method compared with the
RTM method (control). The study included no arm with
a group given no intervention at all.
We did not include specific self-reported mood ques-
tionnaires after the interventions, but instead used a
Parkinson’s disease-specific UPDRS I questionnaire [17].
A specific, sensitive questionnaire for depression and anx-
iety was not administered. It would be important to con-
duct further similar studies in bigger PD groups and/or
other patients with chronic diseases and pain, to repeat
and revaluate these positive short-term effects, before we
can conclude the generalisability of the trial findings.Conclusion
Diurnal cortisol rhythm was normal in PD. Both TM
and RTM interventions resulted in short-term significant
decreases in salivary cortisol concentration and total se-
cretion of cortisol during the day, with no significant dif-
ference between the groups. The effects on the HPA axis
were dependent on the time-point of the intervention
(first or eighth). A tendency towards a more pronounced
decrease in cortisol concentration was seen when TM
was added to the treatment. Cortisol concentrations at
baseline and during the follow-up period were independ-
ent of age, gender, weight, BMI, and levodopa dose. The
total diurnal cortisol secretion was lower during the day
(8 am–8 pm) versus during the night (8 pm–8 am) at
baseline. There was no recognisable long-term effect of
the interventions on the HPA axis in terms of diurnal
cortisol rhythm or total cortisol secretion.Additional file
Additional file 1: Short description of the Tactile Massage concept.
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